Search results for "Pharmacoeconomic assessment"

showing 1 items of 1 documents

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

2011

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease. Objective: The objective of this study was to estimate the potential health benefits, costs, and cost-effectiveness of vaccination with PCV-13 in the Community of Valencia and to generate valuable information for policy makers at regional and country levels. Methods: A decision tree was designed to determine the health and economic outcomes in hypothetical cohorts of vaccinated and unvaccinate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCost effectivenessPharmacoeconomic assessmentCost-Benefit AnalysisPneumococcal conjugate vaccinePneumococcal InfectionsHerd immunityPneumococcal VaccinesIndirect costsYoung AdultEnvironmental healthmedicineHeptavalent Pneumococcal Conjugate VaccineHumansChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfant NewbornInfantMiddle AgedQuality-adjusted life yearVaccinationInfectious DiseasesSpainChild PreschoolCohortMolecular MedicineCost-effectivenessFemalebusinessmedicine.drugVaccine
researchProduct